Fundraising FoxParagon Biosciences LLC — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.
BiotechMedical Devices
Jeff Aronin(Founder)
Co-investorsBain Capital Life SciencesFidelity InvestmentsValor Equity Partners
Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.
BiotechDeep TechMedical DevicesExton, US
Matthew Gantz(President and Chief Executive Officer)inDavid ChuinMichael TownsleyChristopher J. LarsoninRhea WilliamsinJude Sullivan(Executive Officer)
Co-investorsValor Equity PartnersFidelity InvestmentsHorizon
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.